lncRNA TPTEP1 competitively sponges miR ‑328‑5p to inhibit the proliferation of non‑small cell lung cancer cells.

lncRNA TPTEP1 competitively sponges miR‑328‑5p to inhibit the proliferation of non‑small cell lung cancer cells. Oncol Rep. 2020 Feb 26;: Authors: Cao F, Wang Z, Feng Y, Zhu H, Yang M, Zhang S, Wang X Abstract Accumulating evidence suggests that lncRNAs are involved in almost all normal physiological processes and that aberrant expression of lncRNAs may be involved in the development of diseases, including non‑small cell lung cancer (NSCLC). However, the roles of lncRNA‑TPTE pseudogene 1 (TPTEP1) in lung cancer and the underlying molecular mechanisms have remained elusive. In the present study, significant downregulation of TPTEP1 in tumors compared with normal tissues from patients with NSCLC was observed. Overexpression of TPTEP1 inhibited cell proliferation and induced apoptosis in NSCLC cells. A bioinformatics analysis based on miRDB predicted microRNA (miR)‑328‑5p as a potential binding miRNA for TPTEP1. Using a dual‑luciferase reporter assay and western blot analysis, it was further validated that TPTEP1 sponged miR‑328‑5p to upregulate Src kinase signaling inhibitor 1 (SRCIN1) in NSCLC cells. Through regulation of SRCIN1, TPTEP1 was indicated to inactivate the Src and STAT3 pathways in NSCLC cells. Notably, silencing of SRCIN1 reversed the TPTEP1 overexpression‑induced inhibition of cell proliferation and increase of the apoptotic rate in NSCLC cells. Pearson correlation analysis revealed a significant positive corre...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Conditions:   Metastatic Non-small Cell Lung Cancer (NSCLC);   Non-squamous NSCLC Interventions:   Drug: ABP 215;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin Sponsors:   Amgen;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: LINC00460 is overexpressed in NSCLC tissues and can promote the growth of NSCLC cells by targeting miR-539. PMID: 32633366 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 9 July 2020Source: The Annals of Thoracic SurgeryAuthor(s): Shane P. Smith, Adam J. Bograd, Gal Levy, Shu-Ching Chang, Alex S. Farivar, Ralph W. Aye, Brian E. Louie, Eric Vallières
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSIONS: Coverage of ctDNA-based panel testing for cancer indications increased from 2015 to 2019. The trend in private payer and Medicare coverage is an increasing number of coverage policies, number of positive policies, and scope of coverage. We found that Medicare coverage policies are evolving to pan-cancer uses, signifying a significant shift in coverage frameworks. Given that genomic medicine is rapidly changing, payers and policymakers (eg, guideline developers) will need to continue to evolve policies to keep pace with emerging science and standards in clinical care. PMID: 32634780 [PubMed - as supplied by publisher]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
czyk Aptamers are short, single-stranded oligonucleotides which are capable of specifically binding to single molecules and cellular structures. Aptamers are also known as “chemical antibodies”. Compared to monoclonal antibodies, they are characterized by higher reaction specificity, lower molecular weight, lower production costs, and lower variability in the production stage. Aptamer research has been extended during the past twenty years, but only Macugen® has been accepted by the Food and Drug Administration (FDA) to date, and few aptamers have been examined in clinical trials. In vitro s...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Lung cancer is a major threat to human health. The 2018 global cancer statistics reported that lung cancer has the highest morbidity and mortality of all malignant tumors in the world[1] and nonsmall cell lung cancer (NSCLC) accounts for more than 80% of new diagnoses[2]. Despite the rapid development of anti-tumor therapy in stage I-III NSCLC, 30-60% of the patients progress to metastatic diseases [3]. Moreover, the prognosis of NSCLC is still poor when treated with the combination of neoadjuvant therapy, surgical treatment and adjuvant therapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study aims to compare the efficacy of ICIs with conventional therapy in NSCLC patients with bone, brain or liver metastases.Materials and Methods: MEDLINE, Embase, and CENTRAL were searched for studies comparing ICIs with conventional therapy in NSCLC patients with bone, brain or liver metastases. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) among included studies was analyzed using the random effects model.Results: Eight studies consisting of 988 NSCLC patients were included, 259 with brain metastases and 729 with liver metastases. No available study with bone metastases i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract N-[18F]fluoroacetylcrizotinib, a fluorine-18 labeled derivative of the first FDA approved tyrosine kinase inhibitor (TKI) for the treatment of Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), crizotinib, was successfully synthesized for use in positron emission tomography (PET). Sequential in vitro biological evaluation of fluoracetylcrizotinib and in vivo biodistribution studies of [18F]fluoroacetylcrizotinib demonstrated that the biological activity of the parent compound remained unchanged, with potent ALK kinase inhibition and effective tumor growth inhibition. These res...
Source: Bioorganic and Medicinal Chemistry Letters - Category: Chemistry Authors: Tags: Bioorg Med Chem Lett Source Type: research
Abstract c-MET-positive NSCLC is an important subtype accounting for about 5%~22% of lung cancer. NSCLC patients with activating c-MET are intensively sensitive to c-MET selective receptor tyrosine kinase (RTK) inhibitors, so we aimed to develop a specific PET probe targeting to c-MET-positive NSCLC for potential patients screened by PET/CT. Herein, PET tracer 18F-radiolabeled crizotinib derivative ([18F]FPC) was successfully achieved through a simple one-step 18F-labeling method. [18F]FPC PET imaging on c-MET-positive (as well as blocking group) and negative NSCLC models were further evaluated, and results showed...
Source: Bioorganic and Medicinal Chemistry - Category: Chemistry Authors: Tags: Bioorg Med Chem Source Type: research
Contributors : Sara Waise ; Christopher J HanleySeries Type : Expression profiling by high throughput sequencing ; Third-party reanalysisOrganism : Homo sapiensFibroblasts are functionally heterogeneous cells, capable of promoting and suppressing tumour progression. Across cancer types, the extent and cause of this phenotypic diversity remains unknown. We used single-cell RNA sequencing and multiplexed immunohistochemistry to examine fibroblast heterogeneity in human lung and non-small cell lung cancer (NSCLC) samples. This identified seven fibroblast subpopulations: including inflammatory fibroblasts and myofibroblasts (r...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Third-party reanalysis Homo sapiens Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study